[go: up one dir, main page]

ECSP12011842A - ARILINDENOPIRIMIDINAS SUSTITUIDAS CON ALQUILO Y SU USO COMO ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a ALTAMENTE SELECTIVOS - Google Patents

ARILINDENOPIRIMIDINAS SUSTITUIDAS CON ALQUILO Y SU USO COMO ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a ALTAMENTE SELECTIVOS

Info

Publication number
ECSP12011842A
ECSP12011842A ECSP12011842A ECSP12011842A EC SP12011842 A ECSP12011842 A EC SP12011842A EC SP12011842 A ECSP12011842 A EC SP12011842A EC SP12011842 A ECSP12011842 A EC SP12011842A
Authority
EC
Ecuador
Prior art keywords
arilindenopirimidinas
rent
antagonists
replaced
highly selective
Prior art date
Application number
Other languages
English (en)
Inventor
Paul Jackson
Brian Christopher Shook
Aihua Wang
Mark Powell
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ECSP12011842A publication Critical patent/ECSP12011842A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta invención se relaciona con una nueva arilindenopirimidina, A, y sus usos terapéuticos y profilácticos. Los trastornos que se tratan y/o previenen incluyen la enfermedad de Parkinson.en donde X, R2, R3, y R4 son como se definieron en la descripción.
ECSP12011842 2009-10-29 2012-04-27 ARILINDENOPIRIMIDINAS SUSTITUIDAS CON ALQUILO Y SU USO COMO ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a ALTAMENTE SELECTIVOS ECSP12011842A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25592809P 2009-10-29 2009-10-29

Publications (1)

Publication Number Publication Date
ECSP12011842A true ECSP12011842A (es) 2012-06-29

Family

ID=43216968

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12011842 ECSP12011842A (es) 2009-10-29 2012-04-27 ARILINDENOPIRIMIDINAS SUSTITUIDAS CON ALQUILO Y SU USO COMO ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a ALTAMENTE SELECTIVOS

Country Status (9)

Country Link
US (1) US20110105541A1 (es)
CN (1) CN102596938A (es)
AU (1) AU2010313575A1 (es)
CA (1) CA2779095A1 (es)
EC (1) ECSP12011842A (es)
IL (1) IL219335A0 (es)
MX (1) MX2012005001A (es)
PH (1) PH12012500807A1 (es)
WO (1) WO2011053508A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2927225B1 (en) * 2012-11-30 2018-10-03 LG Chem, Ltd. Novel compound and organic electronic element using same
US11161850B2 (en) 2018-07-05 2021-11-02 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6958328B2 (en) * 2001-04-18 2005-10-25 Ortho-Mcneil Pharmaceutical, Inc Arylindenopyridines and related therapeutic and prophylactic methods
US20040127510A1 (en) * 2002-04-16 2004-07-01 Heintzelman Geoffrey R. Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods
ES2326075T3 (es) * 2003-10-03 2009-09-30 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Arilidenopiridinas y arilidenopirimidinas y su uso como antagonistas del receptor de adenosina a2a.

Also Published As

Publication number Publication date
US20110105541A1 (en) 2011-05-05
IL219335A0 (en) 2012-06-28
AU2010313575A1 (en) 2012-05-17
CA2779095A1 (en) 2011-05-05
CN102596938A (zh) 2012-07-18
PH12012500807A1 (en) 2012-11-26
WO2011053508A1 (en) 2011-05-05
MX2012005001A (es) 2012-06-12

Similar Documents

Publication Publication Date Title
NI201000005A (es) Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico.
SMT201500097B (it) Derivati di 4-amminopirimidina e loro uso come antagonsiti del recettore di adenosina a2a
CR8718A (es) Compuesto de morfolina sustituida para el tratamiento de trastornos del sistema nervioso central
ECSP11011243A (es) Agonistas y antagonistas de los receptores s1p5 y metodos de usos similares aplicaciones relacionadas
ECSP034884A (es) Ligandos del receptor de 5-ht y sus usos
UY30917A1 (es) Moduladores 2-aminopiridina del receptor histamina h
CL2008001335A1 (es) Compuestos derivados de pirrolopirimidin-7-ona, antagonistas de los receptores de purina p2x; porceso de preparacion de estos; composicion farmaceutica que los comprende; proceso de preparacion de compuestos intermediarios y usos en el tratamientos del dolor, vejiga hiperactiva, entre otras.
CO6361994A2 (es) Antagonistas del receptor de orexina de isonicotinamida
ECSP055699A (es) Indazoles, benzotiazoles y benzoisotiazoles, y su preparacion y usos
GT201300164A (es) Derivados de biciclo (3.2.1.) octilamida y sus usos
CR11562A (es) Bis-piridilpiridonas como antagonistas del receptor 1 de la hormona concentradora de melanina
CO6321169A2 (es) Metilenaminas de tieno[2,3-d] pirimidina y su uso como antagonistas de receptores de adenosina a2a
CR10243A (es) "bencimidazoles 2-sustituidos como modulares de receptor de androgeno selectivos"
GT201000179A (es) "antagonistas del receptor mineralcorticoide y metodos de uso"
ATE458740T1 (de) 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten
NI201000015A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
UY31420A1 (es) Arilindenopirimidinas y su uso como antagonistas del receptor a2a de adenosina
ECSP12011842A (es) ARILINDENOPIRIMIDINAS SUSTITUIDAS CON ALQUILO Y SU USO COMO ANTAGONISTAS DEL RECEPTOR DE ADENOSINA A2a ALTAMENTE SELECTIVOS
UY31717A1 (es) (pirazolilcarbonil) imidazolidinonas sustituidas y su uso
ECSP12011840A (es) Arilindenopirimidinas sustituidas con heteroarilo y su uso como antagonistas del receptor de adenosina a2a altamente selectivos
PA8801401A1 (es) Arilindenopirimidinas y su uso como adenosina a2a
CL2015000890A1 (es) Compuestos derivados de etinilo como moduladores de la actividad del receptor mglur5; proceso de obtencion; composicion farmaceutica que lo contiene; uso en el tratamiento de ansiedad, dolor, depresion, enfermedad de parkinson, entre otras.
ECSP12011841A (es) ARILINDENOPIRIMIDINAS SUSTITUIDAS CON HETEROCICLILO Y SU USO COMO ANTAGONISTAS DE LOS RECEPTORES DE ADENOSINA A2a ALTAMENTE SELECTIVOS
ECSP12011844A (es) 2-amino-9-[4-(4-metoxi-fenoxi)-piperidin-1-il]-4-fenil-indeno[1,2-d]pirimidin-5-ona y su uso como un antagonista del receptor de adenosina a2a altamente selectivo
ECSP12011843A (es) Arilindenopirimidinas sustituidas con arilo y su uso como antagonistas de receptores de adenosina a2a altamente selectivos